Inclusion body myositis (IBM) is a progressive muscle disease that requires careful diagnostic evaluation to distinguish it from other similar conditions. The diagnosis process often involves multiple steps, from initial symptom assessment to specialized testing, and accurate identification is essential for proper disease management and understanding prognosis.

Introduction: Who Should Seek Diagnostic Testing

If you notice gradual muscle weakness that seems to worsen over time, especially after age 45 or 50, it may be time to consult a healthcare provider. Inclusion body myositis is most commonly diagnosed in people over 50 years of age, and it affects men about two to three times more often than women.^[1][2] The disease often begins so slowly that many people realize they have been experiencing symptoms for years before seeking medical attention.^[3]

You should seek diagnostic evaluation if you experience frequent falls, difficulty getting up from a chair, trouble climbing stairs, or notice that you’re having problems with tasks requiring finger control, such as buttoning shirts, writing with a pen, or gripping objects.^[3][4] Some people first notice a “foot drop” when walking, causing them to trip more often. Others may see visible shrinking of muscles, particularly in the forearms and thighs.^[3]

Difficulty swallowing, known as dysphagia, is another important symptom that should prompt medical evaluation. This occurs in approximately half of people with IBM and, in rare cases, may even be the first symptom noticed.^[1][3] Unlike many muscle diseases, IBM typically causes painless weakness, though some people experience mild, frequent muscle discomfort.^[1]

It’s important to seek care relatively early because diagnostic delays are common with IBM. The disease can be mistaken for other muscle conditions, and some patients don’t receive a proper diagnosis for months or even years.^[8][12] Getting an accurate diagnosis helps you understand your condition, plan for the future, and connect with appropriate support services.

Classic Diagnostic Methods

Diagnosing inclusion body myositis requires a combination of approaches because no single test can definitively identify the disease on its own. Your healthcare provider will typically start with a thorough review of your medical history and a physical examination of your muscles.^[1] This initial assessment helps distinguish IBM from other similar conditions like polymyositis (another type of muscle inflammation) and myasthenia gravis (a condition affecting nerve-muscle communication).

Physical Examination Features

During the physical exam, your doctor will look for specific patterns of muscle weakness that are characteristic of IBM. These distinguishing features include which specific muscle groups are affected, whether one side of your body is more affected than the other, whether you have visible muscle wasting (called atrophy), and your age when symptoms first appeared.^[1] In IBM, weakness typically has an asymmetric distribution, meaning it may be more pronounced on one side than the other.^[3]

IBM shows a characteristic pattern of weakness that sets it apart from other muscle diseases. While most muscle conditions cause weakness in muscles closer to the body’s center (proximal muscles), IBM typically affects the muscles that flex the fingers and the quadriceps muscles at the front of the thighs.^[3] The forearm muscles and muscles that lift the front of the foot are also commonly involved.^[3]

Blood Tests

Laboratory testing plays an important role in the diagnostic process, though blood tests alone cannot confirm IBM. Your healthcare provider will likely order a creatine kinase (CK) test, which measures levels of a specific enzyme in your blood.^[1] When muscles are damaged, they release this enzyme into the bloodstream. In IBM, CK levels are typically elevated, but usually not more than 15 times the upper limit of normal, which helps distinguish it from other muscle conditions where levels may be much higher.^[8]

Your doctor may also order blood tests to screen for viruses and various autoantibodies (proteins produced when the immune system mistakenly attacks the body’s own tissues).^[1] Some people with IBM have anti-cN1A autoantibodies, which support the idea that the disease has an immune-mediated component.^[3]

Electromyography and Nerve Conduction Studies

Electromyography (EMG) is a test that evaluates the electrical activity of muscles and the nerves that control them. During this procedure, a thin needle electrode is inserted into the muscle to record its electrical activity. This test helps determine whether muscle weakness is caused by a muscle disorder (myopathy) or a nerve problem (neuropathy).^[7] Nerve conduction studies may be performed alongside EMG to provide additional information about nerve function.

Imaging Studies

Muscle imaging with magnetic resonance imaging (MRI) can be helpful in the diagnostic process. An MRI uses magnets and radio waves to create detailed pictures of the muscles, showing areas of inflammation, muscle damage, or atrophy. MRI studies may be ordered to identify which muscles are affected and to help guide the selection of an appropriate site for muscle biopsy.^[7]

Muscle Biopsy: The Most Specific Test

A muscle biopsy remains the most specific and critical diagnostic test for confirming inclusion body myositis.^[7] This procedure involves removing a small piece of muscle tissue, usually from a thigh muscle or the biceps muscle, for examination under a microscope. The tissue is analyzed for specific features that are characteristic of IBM.

During a muscle biopsy, local anesthetic is applied to numb the area, and then a small surgical incision is made to remove the muscle sample. This is considered a minor surgical procedure.^[7] The muscle tissue is then examined in a laboratory for several distinctive features that help confirm the diagnosis.

Diagnostic Criteria

Several diagnostic criteria have been developed to help doctors identify IBM. The European Neuromuscular Centre (ENMC) 2011 criteria are among the most widely used.^[8] According to these criteria, certain features must be present for a diagnosis, including age of onset later than 45 years, symptoms lasting more than 12 months, and serum creatine kinase levels not more than 15 times the upper limit of normal.

Clinical features that support the diagnosis include weakness of the quadriceps muscles (more than hip flexors) and weakness of finger flexors (more than shoulder muscles). Pathological features found on muscle biopsy that support the diagnosis include inflammatory cells infiltrating the muscle tissue, rimmed vacuoles (empty spaces with a distinctive border), protein accumulations, and increased expression of certain immune markers on muscle cells.^[8]

Based on the combination of clinical and pathological features, IBM can be classified as “clinicopathologically defined” (meeting all mandatory criteria plus clinical and pathological features), “clinically defined” (meeting mandatory and clinical criteria plus some pathological features), or “probable” (meeting mandatory criteria plus one clinical criterion and some pathological features).^[8]

Diagnostics for Clinical Trial Qualification

When patients are being considered for enrollment in clinical trials studying potential treatments for inclusion body myositis, additional diagnostic testing and qualification criteria may be required beyond standard diagnostic procedures. Clinical trials often have very specific entry requirements to ensure that participants truly have IBM and that the study results will be meaningful.

For clinical trial purposes, researchers typically require confirmed diagnosis based on established diagnostic criteria, often using the ENMC 2011 criteria or similar validated classification systems.^[8] This ensures that all participants in the study have been diagnosed using the same standards, making the results more reliable and comparable.

Muscle biopsy confirmation is frequently required for clinical trial enrollment, as this provides the most definitive evidence of IBM. The biopsy must show the characteristic features of the disease, including the presence of inclusion bodies, inflammatory infiltrates, and vacuolar changes in muscle fibers.^[3][8]

Clinical trials may also require baseline measurements of muscle strength and function to establish a starting point for comparison. These measurements help researchers determine whether a treatment is having an effect. Standardized strength testing of specific muscle groups, particularly the finger flexors and knee extensors, is commonly performed.^[12]

Some trials require assessment of functional abilities, such as walking distance, time to rise from a chair, or ability to perform daily activities. Researchers may use standardized questionnaires or functional assessment scales to measure these abilities at the start of the trial and at regular intervals throughout the study.^[12]

Laboratory testing is often repeated for clinical trial qualification to ensure that blood markers fall within acceptable ranges. Creatine kinase levels, complete blood counts, liver and kidney function tests, and other laboratory values may need to meet specific criteria for enrollment. Some trials also test for specific antibodies or genetic markers that might influence response to treatment.^[8]

Age criteria are typically specified in clinical trial protocols, as IBM predominantly affects people over 40 or 45 years of age. Trials may exclude people who are too young or, in some cases, those above a certain age.^[4][12] Duration of symptoms is another common qualification criterion, as trials often want to study people at specific stages of disease progression.

Imaging studies, particularly muscle MRI, may be required for some clinical trials to document the pattern and extent of muscle involvement at baseline. This imaging can then be repeated during the trial to see if the treatment affects muscle inflammation or prevents further muscle damage.^[12]

Respiratory function testing may be required in some trials, particularly those studying treatments that might affect breathing muscles or swallowing function. Tests like pulmonary function testing measure how well the lungs are working.^[4]

Swallowing assessments may also be part of trial qualification procedures, especially for studies examining therapies that might help with dysphagia. Speech therapists can perform specialized swallowing evaluations to document baseline swallowing function.^[7]

Previous treatment history is carefully reviewed during clinical trial screening. Some trials exclude people who have received certain immunosuppressive medications within a specified time period, while others may require that participants have tried and not responded to standard treatments. This information helps researchers understand whether the study treatment offers something different from existing options.^[13]

Documentation of disease progression may be required, with records showing how symptoms have changed over time. This helps establish the natural course of the disease in that individual and provides context for evaluating whether a treatment is slowing progression.^[12]